Nurix Therapeutics, Inc. NRIX

23.08 (0.57) (2.41%) as of 25 Sep

Market cap: $2.5B
P/E: 0.0×

Follow NRIX

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

	Nov '25	Nov '24	Nov '23	Nov '22	Nov '21	Nov '20	Nov '19	Nov '18	Nov '17
Cash and Short Term Investments	592.94	609.58	287.91	309.14	295.72	281.15	37.72	39.04	—
Receivables	—	—	—	1.10	6.20	3.85	—	—	—
Other current assets	—	—	—	8.21	8.29	7.50	1.63	1.62	—
Total current assets	606.82	619.39	295.50	318.45	311.12	298.43	39.35	40.65	—
Property, Plant, Equpment (Net)	22.49	17.76	16.81	17.16	11.34	6.67	3.87	4.42	—
Long-Term Investments	—	—	7.42	63.88	137.19	90.89	0.51	0.17	—
Long-term assets (Other)	8.31	4.06	4.72	4.92	3.12	0.35	0.32	0.32	—
Total non-current assets	81.32	49.96	60.10	98.31	165.65	97.91	4.69	4.74	—
Total Assets	688.14	669.34	355.60	416.76	476.77	396.34	44.05	45.40	0.00
Accounts Payable	11.22	11.48	6.40	5.06	6.65	3.41	1.60	1.30	—
Accrued Expenses	54.85	37.99	24.97	22.43	14.55	8.33	4.93	3.12	—
Current Revenue (Deferred)	17.58	38.36	48.10	37.63	41.21	32.80	9.61	28.42	—
Total current liabilities	86.47	95.85	86.96	70.66	66.26	44.54	16.14	32.83	—
Non-current Revenue (Deferred)	10.01	26.21	45.02	35.97	59.02	60.69	35.69	—	—
Liabilities (Preferred Stock)	—	—	—	—	—	—	48.20	48.20	—
Non-current Liabilities (Other)	—	—	—	—	—	0.85	1.74	1.22	—
Total non-current liabilities	62.92	46.50	68.15	42.41	68.21	61.54	85.63	49.41	—
Total liabilities	149.39	142.35	155.11	113.06	134.47	106.07	101.76	82.24	—
Additional Paid In Capital	1,541.77	1,265.54	746.30	709.22	563.76	393.84	2.74	1.91	—
Common Stock (Net)	0.10	0.08	0.05	0.05	0.05	0.04	0.00	0.00	—
Retained Earnings	(1,003.23)	(738.77)	(545.20)	(401.25)	(220.89)	(103.70)	(60.46)	(38.76)	—
Common Equity (Total)	538.75	526.99	200.49	303.70	342.30	290.27	(57.71)	(36.85)	—
Shareholders Equity (Total)	538.75	526.99	200.49	303.70	342.30	290.27	(57.71)	(36.85)	—
Shareholders Equity and Liabilities (Total)	688.14	669.34	355.60	416.76	476.77	396.34	44.05	45.40	—
Shares (Common)	101.81	75.87	48.72	47.17	44.66	38.87	3.60	37.04	—
Shares (Preferred)	—	—	—	—	—	—	12.81	—	—
Shareholders Equity (Tangible)	538.75	526.99	200.49	303.70	342.30	290.27	(57.71)	(36.85)	—
Net Debt	(592.94)	(609.58)	(287.91)	(309.14)	(295.72)	(281.15)	(37.72)	(39.04)	—
Total Debt	—	—	—	11.96	13.04	—	—	—	—

Show all line items

In millions of $ except per-share values · columns are period end dates

Powerpack

Full quarterly history

Analyst estimates

Unlimited screener

Unlimited Excel

Unlimited follows

Nurix Therapeutics, Inc. NRIX